SCHEMBL4486386

SCHEMBL4486386

O=C(c1ccc(O)cc1)N1CCN(Cc2ccccc2)CC1

nearest known ligand 0.82

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.78
ALDH1A1 P00352 1/20 0.78
MEN1 O00255 3/20 0.71
KMT2A Q03164 3/20 0.71
LMNA P02545 2/20 0.71
MAPK1 P28482 2/20 0.71
TSHR P16473 1/20 0.71
SMN1; SMN2 Q16637 1/20 0.71
L3MBTL1 Q9Y468 1/20 0.71
SIGMAR1 Q99720 1/20 0.71
CA12 O43570 1/20 0.69
CA1 P00915 1/20 0.69
CA2 P00918 1/20 0.69
CA7 P43166 1/20 0.69
CA9 Q16790 1/20 0.69
CA14 Q9ULX7 1/20 0.69
NPC1 O15118 1/20 0.68
PKM P14618 1/20 0.67
PRKAB2 O43741 1/20 0.65
PRKAG1 P54619 1/20 0.65

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1019998 0.91 KDM4E (0.94) KDM4EALDH1A1MEN1KMT2ALMNA
SCHEMBL9645824 0.91 KDM4E (0.94) KDM4EALDH1A1MEN1KMT2ALMNA
SCHEMBL13149349 0.88 KDM4E (0.78) KDM4EALDH1A1MEN1KMT2ALMNA
SCHEMBL12452433 0.87 ALDH1A1 (0.76) KDM4EALDH1A1MEN1KMT2ALMNA
SCHEMBL7474168 0.87 KDM4E (0.76) KDM4EALDH1A1MEN1KMT2ALMNA
SCHEMBL25041158 0.87 KDM4E (0.76) KDM4EALDH1A1MEN1KMT2ALMNA
SCHEMBL4516322 0.87 KDM4E (0.76) KDM4EALDH1A1MEN1KMT2ALMNA
SCHEMBL17696082 0.87 KDM4E (0.76) KDM4EALDH1A1MEN1KMT2ALMNA
SCHEMBL10076259 0.85 KDM4E (0.74) KDM4EALDH1A1MEN1KMT2ALMNA
SCHEMBL18753884 0.85 GPR183 (0.59) KDM4EALDH1A1CA12CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101230033-B New azabicycloalkane derivatives, preparing method and medicament combination containing the same SERVIER LAB 2011-03-09 CN disclosed
CN-100577160-C Novel azabicyclo derivatives, preparation method thereof and pharmaceutical compositions containing same SERVIER LAB 2010-01-06 CN disclosed
US-7576120-B2 Azabicyclic compounds, a process for their preparation and pharmaceutical compositions containing them LES LABORATOIRES SERVIER (FR) 2009-08-18 US disclosed
CN-101230033-A New azabicycloalkane derivatives, preparing method and medicament combination containing the same SERVIER LAB (FR) 2008-07-30 CN disclosed
EP-1720544-B1 NOVEL AZABICYCLIC DERIVATIVES, PREPARATION METHOD THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME SERVIER LAB (FR) 2008-03-19 EP disclosed
US-20070197625-A1 Azabicyclic compounds, a process for their preparation and pharmaceutical compositions containing them. LES LABORATORATIES SERVIER (FR) 2007-08-23 US disclosed
CN-1921848-A Novel azabicyclo derivatives, preparation method thereof and pharmaceutical compositions containing same SERVIER LAB (FR) 2007-02-28 CN disclosed
EP-1720544-A1 NOVEL AZABICYCLIC DERIVATIVES, PREPARATION METHOD THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME Les Laboratoires Servier (FR) 2006-11-15 EP disclosed
WO-2005089747-A1 NOVEL AZABICYCLIC DERIVATIVES, PREPARATION METHOD THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME LES LABORATOIRES SERVIER (FR) 2005-09-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070197625-A1 Azabicyclic compounds, a process for their preparation and pharmaceutical compositions containing them. HRH2, HNMT, HRH1 KDM4E 461/4885ALDH1A1 308/4885MEN1 998/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.